Abstracts
Skip to Late-Breaking Abstracts »
Poster Presentation Dates
All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.
Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).
| # | Title | Authors | Category | Keywords |
|---|---|---|---|---|
| O37 | PD1 Blockade Augments Adoptive T Cell Therapy via Endogenous T cells Rather than Direct Enhancement of Transferred T Cells | John S. Davies, PhD; Farrah Karimipour, BS.; Ling Zhang, PhD; Carylinda Serna; Christian S. Hinrichs, MD; | Combination Immunotherapies | Adoptive immunotherapy; Checkpoint blockade; Coinhibition; Neoantigens; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| O38 | A Single-dose immunotherapy that remodels the tumor microenvironment for subsequent curative responses to checkpoint blockade | Chensu Wang, PhD; Chensu Wang, PhD; Ang Cui; Ayush Thomas; Simon Liang; Maurice Bukenya; Heikyun Suh; K. Dane Wittrup, PhD; Nir Hacohen, PhD; Darrell J. Irvine, PhD; | Combination Immunotherapies | Angiogenesis; Antibody; Checkpoint blockade; Cytokine; Dendritic cell; Monocyte/Macrophage; NK/NK T cell; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O39 | Soluble TNFα induced mucin 4 is a mediator of trastuzumab resistance and of an immunosuppressive tumor microenvironment in HER2+ breast cancer | Sofia Bruni, MS; Mara De Martino, PhD; Florencia L. Mauro, MS; Lucia Santa maria de la Parra; Patricia V. Elizalde, PhD; Roxana Schillaci; Roxana Schillaci; | Combination Immunotherapies | Antibody; Immune suppression; Myeloid cells; MDSC; NK/NK T cell; Solid tumors; Targeted therapy; Tumor microenvironment |
| O40 | Immunobiology and clinical activity of CPI-006, an anti-CD73 antibody with immunomodulating properties in a phase 1/1b trial in advanced cancers | Jason J. Luke, MD, FACP; Jaime Merchan; Lauren Harshman, MD; Thomas U. Marron, MD PhD; John D. Powderly, II, MD, CPI; Minal Barve; Patricia LoRusso, DO; Melissa Johnson; Andrew Hotson, PhD; Rachel Gittelman, PhD; Brian Munneke; Joseph J. Buggy; Stephen Willingham, PhD; Emily C. Piccione, PhD; Mehrdad Mobasher; Richard A. Miller, MD; Richard A. Miller; | Combination Immunotherapies | Antibody; Antigen presenting cells; B cell; Checkpoint blockade; Clinical trial; Targeted therapy |
| O41 | Vasoactive intestinal peptide: a novel checkpoint pathway in pancreatic ductal adenocarcinoma | Sruthi Ravindranathan, PhD; Shuhua Wang, MD; Brandon Ware; Mohammad Y. Zaidi, MD, MS; Jingru Zhu; Rohan K. Dhamsania, BS; Susan N. Thomas, PhD, BS; Yiwen Li, MS; Bassel El-rayes, MD; Gregory B. Lesinski, PhD, MPH; Edmund K. Waller, MD, PhD, FACP; | Combination Immunotherapies | Adoptive immunotherapy; Solid tumors; Targeted therapy |
| P462 | ImmTAC®-chemotherapy combination: A preclinical evaluation shows potential benefits | Adel Benlahrech, BSc PhD; Filipa Bravo-Lopes; Nora Rippaus; Kristina Petrovic; Francesca Amicarella; Adam Taylor; Laure Humbert; Rupert Kenefeck; Adel Benlahrech, BSc PhD; | Combination Immunotherapies | Chemotherapy; T cell; Targeted therapy |
| P463 | Immunotherapy combinations for betel-nuts related HNSCC: one institutional experiences in Taiwan | Jo-Pai Chen, MD; Ruey-Long Hong, MD, PhD; Wei-Chen Lu, MD; | Combination Immunotherapies | Checkpoint blockade |
| P464 | IFN-α and 5-Aza-2’-deoxycytidine enhance the anti-tumor efficacy of a dendritic-cell targeting MIP3α-Gp100-Trp2 DNA vaccine by affecting T-cell and Dendritic Cell recruitment into tumor | James Gordy, PhD; Richard Markham, BS MD; | Combination Immunotherapies | Antigen presenting cells; Chemokine; Chemotherapy; Dendritic cell; Immune adjuvant; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P465 | Immune-mediated mechanisms involved in the synergistic anti-tumor efficacy of NHS-IL12 combined with the class I HDAC inhibitor entinostat. | Kristin C. Hicks, PhD; Yohei Ozawa, MD, PhD; Karin M. Knudson, PhD; Jeffrey Schlom; Sofia Gameiro, PharmD, PhD; | Combination Immunotherapies | Cytokine; Immune adjuvant; Immune suppression; Monocyte/Macrophage; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P466 | Carboplatin and paclitaxel after anti-PD1 or anti-PDL1 therapy: A retrospective study in patients with squamous cell carcinoma of the head and neck | Audrey Humphries, BS; Madeleine Welsh, BA; Alain Algazi, MD; | Combination Immunotherapies | Checkpoint blockade; Chemotherapy |
| P467 | ALPN-202, a Conditional CD28 Costimulator and Dual Checkpoint Inhibitor, Enhances the Activity of Multiple Standard of Care Modalities | Katherine E. Lewis, PhD; Mark F. Maurer, BS; Sherri Mudri, BS; Kayla N. Susmilch, MS; Fariha Ahmed-Qadri, MS; Chelsea J. Gudgeon, BS; Steven D. Levin, PhD; Martin Wolfson, BS; Stacey R. Dillon, PhD; Kristine M. Swiderek, PhD; Stanford L. Peng, MD, PhD; | Combination Immunotherapies | Checkpoint blockade; Chemotherapy; Costimulation; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P468 | Targeting the ICOS pathway in combination with chemotherapy to enhance T-cell mediated anti-tumor immune responses | Tamer Mahmoud, PhD; Jeffrey M. Riggs; Madhu Ramaswamy, PhD; Leigh Hostetler; Brian Naiman; Ilyssa Ramos; Sean Turman; Fernanda Pilataxi; Christopher A. Morehouse, MD; Alex Alfaro; Norman Peterson; Ryan Fleming; Nazzareno Dimasi; Kyle Kuszpit; Ronald Herbst; Gianluca Carlesso, PhD; | Combination Immunotherapies | Antibody; Chemotherapy; Costimulation; Metabolism; Regulatory T cell (Treg cell); Solid tumors; T cell |
| P469 | Chemotherapy enhances effector T cell responses to tumor associated antigens in human and mouse pancreatic cancer | Francesco Novelli, PhD; Giorgia Mandili, PhD; Claudia Curcio, PhD; Sara Bulfamante, MS; Laura Follia, MS; Daniele Giordano, MD; Rossella Spadi, MD; Maria Antonietta Satolli, MD; Paola Cappello, PhD MS; Francesco Novelli, PhD; | Combination Immunotherapies | Antibody; Chemotherapy; Proteomics; T cell; Targeted therapy; Tumor antigens; Vaccine |
| P470 | Impact of treatment-induced necrosis in the anti-tumor efficacy of Entinostat combined with the immunocytokine NHS-IL12 | Yohei Ozawa, MD, PhD; Kristin C. Hicks, PhD; Karin M. Knudson, PhD; Jeffrey Schlom; Sofia Gameiro, PharmD, PhD; | Combination Immunotherapies | Cytokine; Monocyte/Macrophage; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P471 | Combination of BL-8040, anti PD-1 and chemotherapy significantly reduced pancreatic tumor growth and changed the balance between CD4+/FOXP3+ cells and CD8+ cells in the tumor | Amnon Peled, PhD; | Combination Immunotherapies | Checkpoint blockade; Chemokine; Chemotherapy; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P472 | STAT3 ASO and Cisplatin combination sensitizes protected tumor microenvironments to checkpoint-mediated therapy | Theresa Proia, PhD; Maneesh Singh, PhD; Nanhua Deng; Minwei Ye; Frank McGrath; Douglas Ferguson; Simon Barry; | Combination Immunotherapies | Antigen presenting cells; Checkpoint blockade; Chemotherapy; Myeloid cells; Tumor microenvironment |
| P473 | Adoptive transfer of Deep IL-12 Primed T cells increases sensitivity to PD-L1 blockade for superior efficacy in checkpoint refractory tumors | Gulzar Ahmad, PhD; Jonathan Nardozzi, PhD; Lars R. Petersen, PhD; Esben Christensen, MSc; Ditte Jaegher; James Suchy, PhD; Karsten Sauer, PhD; Douglas S. Jones, PhD; Thomas L. Andresen, PhD; | Combination Immunotherapies | Adoptive immunotherapy; Cytokine; MDSC; Solid tumors; T cell; Tumor microenvironment |
| P474 | Efficacy and toxicity evaluation of anti-human CD47 and SIRPa antibodies in genetically humanized B-hSIRPa/hCD47 mice | Frank An; Yanan Guo; Jie Xiang; Chaoshe Guo; | Combination Immunotherapies | Antibody; Immune toxicity; T cell |
| P475 | PD1 and LAG3 converge to limit polyfunctionality and systemic immunity. | Lawrence P. Andrews, PhD; Sasikanth Manne; E. John Wherry, PhD; Creg Workman, PhD; Dario A. Vignali, PhD; | Combination Immunotherapies | Checkpoint blockade; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P476 | The combination of a STING agonist with cytokines results in robust anti-tumor effects in autochthonous tumor models | Cristina Blaj, PhD; Yingjoy Li; Allen Chen; Anthony L. Desbien, PhD; Brian Francica, PhD; Sarah McWhirter; Lora Picton; K. Christopher Garcia; David Raulet, PhD; | Combination Immunotherapies | Cytokine; NK/NK T cell; Solid tumors; T cell; Tumor microenvironment |
| P477 | Isoform-specific blockade of active TGFb1 with mAb 13A1 enhances the efficacy of PD-L1 checkpoint therapy in a EMT6 mouse tumor model | Matteo Brioschi; Jacques Van Snick, PhD; Catherine Uyttenhove; Pamela Cheou; George Coukos, MD, PhD; Gerd Ritter; Steven M. Dunn, PhD; Steven M. Dunn, PhD | Combination Immunotherapies | Antibody; Checkpoint blockade; Coinhibition; Cytokine; Immune contexture; Immune suppression; Solid tumors; Tumor evasion; Tumor microenvironment; Tumor stroma |
| P478 | SEMA4D antibody blockade overcomes mechanisms of immune suppression and combination immunotherapy including TGFβ blockade promotes efficient tumor regression | Elizabeth E. Evans, PhD; Terrence L. Fisher, Jr., PhD; Crystal Mallow, BS; Holm Bussler, PhD; Sebold Torno, BS; Desa Rae Pastore; Alan Howell, MS; Luis I. Ruffolo, MD; Nicholas Ullman; Brian A. Belt, JD; Joe Bucukovski; Christine Reilly, BS; Benjamin Dale; Ernest S. Smith, PhD; David C. Linehan, MD; Maurice Zauderer, PhD; Elizabeth E. Evans, PhD; | Combination Immunotherapies | Antibody; Checkpoint blockade; Clinical trial; Immune suppression; Myeloid cells; MDSC; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P479 | Evaluation of a TNFR2 antibody with and without anti-PD-1 therapy in two murine colon cancer models | Katie L. Case; Lisa Tran; Hui Zheng; Michael Yang; Denise L. Faustman, MD, PhD; | Combination Immunotherapies | Antibody; Checkpoint blockade; Regulatory T cell (Treg cell); Solid tumors; Tumor microenvironment |
| P480 | Heterologous Prime-Boost Vaccination Safely Enhances Antitumor Immunity to the Colorectal Antigen GUCY2C | John C. Flickinger, Jr., BS; Robert carlson; Jagmohan Singh; Trevor Baybutt, BS; Elinor Leong; Alicja Zalewski; Amanda Pattison; Jeffrey Rappaport; Joshua Barton; Scott A. Waldman; Adam E. Snook, PhD; John C. Flickinger, Jr., BS; | Combination Immunotherapies | Solid tumors; Targeted therapy; Tumor antigens; Vaccine |
| P481 | Obesity impairs immunotherapeutic efficacy in pre-clinical breast cancer | Justin T. Gibson, BS; Rachael M. Orlandella, BS; William J. Turbitt; Robert E. Sorge, PhD; Lyse A. Norian, PhD; | Combination Immunotherapies | Immune suppression; MDSC; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P482 | STACT: A Novel Therapeutic Platform that Delivers Immunomodulatory Payloads to Tumor-Resident Myeloid Cells After IV Dosing and Demonstrates Potent Anti-Tumor Efficacy in Preclinical Studies | Laura H. Glickman, PhD; Christopher Rae, PhD; Alexandre Iannello, PhD; Anastasia M. Makarova, PhD; Haixing Kehoe, MS; John Faulhaber; Bill Hanson; Christopher Thanos, PhD; | Combination Immunotherapies | Chemokine; Cytokine; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
| P483 | TLR enhanced GVAX elicits tumor-specific tissue resident memory T cells independent of T cell priming | Michael J. Korrer; David Taylor; Young J. Kim, MD, PhD; Michael J. Korrer, PhD; | Combination Immunotherapies | Antigen presenting cells; Immune adjuvant; Myeloid cells; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Vaccine |
| P484 | CB-708, an orally bioavailable small molecule inhibitor of CD73 with immunostimulatory and anti-tumor activity | Clarissa Lee, PhD; Deepthi Bhupathi; Roland Billedeau; Jason Chen; Lijing Chen; Rosalyn Dang; Matthew Gross; Tony Huang; Weiqun Li, PhD; Yong Ma; Andrew MacKinnon; Gisele Marguier, MS; Silinda Neou, MS; Francesco Parlati, PhD; Natalija Sotirovska, MS; Sandra Spurlock; Timothy Stanton; Susanne Steggerda, PhD; Jing Zhang; Winter Zhang; Jim Li; | Combination Immunotherapies | Checkpoint blockade; Chemotherapy; Immune suppression; Solid tumors; T cell; Tumor microenvironment |
| P485 | Synergistic efficacy of anti-PD-L1/IL-15 fusion protein in combination with anti-CTLA-4 antibody in a murine orthotopic 4T1 breast carcinoma model | Stella Martomo, PhD; Dan Lu, MA; Jeegar Patel; Zhanna Polonskaya; Xenia Luna; Kevin McCracken; | Combination Immunotherapies | Antibody; Checkpoint blockade; Cytokine; Gene expression; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P486 | Releasing the break on T cell activation through novel small molecule inhibition of HPK1 | Minhui Shen; Gayathri Bommakanti, PhD; Deanna A. Mele, PhD; Deanna A. Mele, PhD; Neil Grimster, PhD; | Combination Immunotherapies | T cell; Tumor evasion |
| P487 | Combining an engineered costimulatory vaccine with NK cells induces an anti-tumor effect against murine neuroblastoma in vitro and after bone marrow transplant in vivo | Nicholas R. Mohrdieck, BS.; Paul Bates; Sean P. Rinella; Katharine E. Tippins; Christian M. Capitini, MD; | Combination Immunotherapies | Adoptive immunotherapy; Costimulation; Cytokine; Immune adjuvant; NK/NK T cell; Pediatric tumors; Solid tumors; Vaccine |
| P488 | IPH5201, a blocking antibody targeting the CD39 immunosuppressive pathway, unleashes immune responses in combination with cancer therapies. | Pascale Andre; Ivan Perrot; Caroline Denis, PhD; Marc Giraudon-Paoli; Severine Augier; Rachel Courtois; Diana Jecko; Thomas Arnoux; Violette Breso; Nicolas Gourdin, PhD; Nadia Luheshi, PhD; Ariane Morel, PhD; Yannis Morel, PhD; Eric Vivier; Carine Paturel, PhD; | Combination Immunotherapies | Antibody; Checkpoint blockade; Coinhibition; Immune suppression; Solid tumors; T cell; Tumor microenvironment |
| P489 | Identification and characterization of MCLA-145 (CD137 x PD-L1): A bispecific antibody that requires PD-L1 binding to activate CD137. | Simon E. Plyte; Cecile Geuijen; John de Kruif; Pieter Fokko van Loo, PhD; Paul Tacken; vanessa Zondag-vander Zande; Rinse klooster; hans van Maaden; Erik Rovers; steef engels; floris franzen; abdul basmeleh; willem bartelink; Mark Throsby; Patrick Mayes; Horacio Nastri; shaun stewart; jing zhou; steve wang; Chen-yen Huang; thomas codamine; ashwini kularni; yao bin lui; arpita mondal; leslie hall; soeon kim; marina martinez; shaun o'brien; edmund moon; steven albelda; | Combination Immunotherapies | Antibody; Checkpoint blockade; Costimulation; T cell; Targeted therapy |
| P490 | Antibody derived from an elite responder to checkpoint inhibitor therapy relieves immunosuppression by tumor associated macrophages | Randi Simmons; Siddarth Chandrasekaran; Melissa Conerly; Tyrel Smith; Sam Lam; Jacqueline Pham; Ray Fox; Darbie Whitman; Meghan Zuck; Sara Carbonetti; Kamal D. Puri, PhD; | Combination Immunotherapies | Antibody; Checkpoint blockade; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; T cell; Targeted therapy; Tumor evasion; Tumor microenvironment |
| P491 | Preclinical Development of a Novel TNFRSF25 Agonist Antibody, PTX-35, for Cancer Immunotherapy Combinations | Matthew M. Seavey, PhD; Jayalakshmi Miriyala, MS; Jason Rose, MS; Vikas Tahiliani, PhD; Patrick Dillon, PhD; Elena Gorovits, PhD; Jeff Hutchins, PhD; Rahul R. Jasuja, PhD; | Combination Immunotherapies | Antibody; Immune adjuvant; Inflammation; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Vaccine |
| P492 | A new generation anti-TGFβ antibody, SAR439459, relieves immunosuppression and improves anti-tumor efficacy of PD1 blockade | Rita M. Greco; Hongjing Qu; Joachim Theilhaber; Gary Shapiro; Richard Gregory, PhD; Christopher Winter; Natalia Malkova; Lily Pao; Mikhail Levit; Alexei Protopopov; Jack Pollard, PhD; Tun Tun Lin, MD; Dmitri Wiederschain; Sharad Sharma, PhD; | Combination Immunotherapies | Coinhibition; Immune suppression; T cell; Tumor microenvironment |
| P493 | High-Dimensional Analysis Delineates Modulation of Myeloid and Lymphoid Compartments with STAT3 ASO and PDL-1 combination Therapy | Theresa Proia, PhD; Maneesh Singh, PhD; Larissa S. Carnevalli, PhD; Gayathri Bommakanti, PhD; Nanhua Deng; Matthew Griffin; Lukasz Magiera; Adina Hughes; Laura Prickett; Patricia McCoon, PhD; Corinne Reimer; Simon Barry, PhD; | Combination Immunotherapies | Checkpoint blockade; Immune suppression; Monocyte/Macrophage; Myeloid cells; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P494 | A Novel TNFRSF25 Agonist, PTX35, Synergizes with Gp96-Ig/OX40L-Ig to Enhance Effector and Memory Anti-Tumor CD8+ T Cell Responses and Delay Tumor Growth | Vikas Tahiliani; Patrick Dillon, PhD; Jayalakshmi Miriyala, MS; Jason Rose, MS; Anh Trinh; Rahul R. Jasuja, PhD; Jeff Hutchins, PhD; Matthew M. Seavey, PhD; | Combination Immunotherapies | Antibody; Immune adjuvant; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Vaccine |
| P495 | Secondary immune resistance mechanisms induced by therapeutic cancer vaccines which prevent tumor regression and foster recurrences. | Sjoerd H. Van der Burg, PhD; Elham Beyranvand Nejad; Camilla Labrie; Suzanne van Duikeren, Ing; Ramon Arens, PhD; Thorbald van Hall, PhD; Sjoerd H. van der Burg, PhD; | Combination Immunotherapies | Checkpoint blockade; Cytokine; Immune contexture; Inflammation; Myeloid cells; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Tumor stroma; Vaccine |
| P496 | Inhibition of Autophagy Enhances Multifunctional Genetically-Engineered NK cell-Based Immunotherapy of Glioblastoma | Jiao Wang, PhD; Sandro Matosevic, PhD; Jiao Wang, PhD; | Combination Immunotherapies | Adoptive immunotherapy; Antibody; Checkpoint blockade; Chemokine; Immune suppression; NK/NK T cell; Solid tumors; Targeted therapy; Tumor evasion; Tumor microenvironment |
| P497 | DRP-104, A Novel Broad Acting Glutamine Antagonist, Induces Distinctive Immune Modulation Mechanisms and Synergistic Efficacy in Combination with Immune Checkpoint Blockade | Yumi Yokoyama, PhD; Michael Nedelcovych, PhD; Robert Wild, PhD; | Combination Immunotherapies | Checkpoint blockade; Monocyte/Macrophage; Metabolism; NK/NK T cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P498 | Blockade of PD-1 and LAG-3 on CD8+ T cells, induced by vaccination, elicits superior anti-tumor efficacy | Christopher W. Zahm, PhD; Douglas G. McNeel, MD, PhD; Laurne E. Delmastro; | Combination Immunotherapies | Antigen presenting cells; Checkpoint blockade; Dendritic cell; Solid tumors; T cell; Tumor evasion; Tumor microenvironment; Vaccine |
| P499 | Nano-Pulse Stimulation in combination with the TLR 7/8 agonist, resiquimod, synergizes to eliminate murine melanoma through innate and adaptive immune responses | Joel Benjamin, PhD; Amanda McDaniel, BA; Kristin von Rothstein; Sasha Farina; Bruce Freimark, PhD; Richard Nuccitelli, MS, PhD; | Combination Immunotherapies | Antigen presenting cells; Biomarkers; Dendritic cell; Immune adjuvant; TLR; Tumor antigens; Tumor microenvironment; Vaccine |
| P500 | Targeting PARP-1 with metronomic therapy as a new approach to modulate MDSC function and enhance anti-PD1 immunotherapy in colon cancer | Salome Valentina Ibba, PhD; Mohamed Ghonim; Abdelmetalab Tarhuni; Matthew Dean; Hamid Boulares, PhD; Augusto C. Ochoa, MD; Youssef Errami; Ali Elbahraway; Ilyes Benslimane; Dorota Wyczechowska; Luis Del Valle, MD; Amir Al-Khami; Hanh Luu; | Combination Immunotherapies | Checkpoint blockade; Cytokine; Gene expression; Immune suppression; Inflammation; MDSC; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P501 | Dietary deprivation of non-essential amino acids improves anti-PD-1 immunotherapy in murine colon cancer | Xiyan Li, PhD; Zehui Li, PhD; Grace X. Yang, PhD; Shuang Zhou, PhD; Xin Wang, MD, PhD; Xiyan Li, PhD; | Combination Immunotherapies | Metabolism; Solid tumors |
| P502 | In Vitro and In Vivo RRx-001 Synergy with Regorafenib and In Vivo Attenuation of Regorafenib-Induced Toxicity | Bryan Oronsky, MD PhD; Tony Reid, MD PhD; Corey A. Carter, MD; Christopher Larson, MD PhD; Pedro Cabrales, PhD; | Combination Immunotherapies | Costimulation; Immune adjuvant; Immune tolerance; Immune toxicity; Solid tumors |
| P503 | Local treatment with adenovirus expressing TNF-α and IL-2 proteins promotes abscopal effect in mice receiving anti-PD-1 immunotherapy | Dafne C. Quixabeira; Victor Cervera-Carrascon, MS; Joao M. Santos, MS; Riikka Havunen; Akseli Hemminki, MD, PhD; | Combination Immunotherapies | Checkpoint blockade; Cytokine; Solid tumors; T cell; Tumor microenvironment |
| P504 | ¬Arginase therapy combines effectively with checkpoint blockade or agonist anti-OX40 immunotherapy to control tumor growth | William L. Redmond, PhD; Annah S. Rolig, Ph. D; Scott Rowlinson, PhD; Melissa J. Kasiewicz, BS; Mark D. Badeaux, PhD; William L. Redmond, PhD; Giulia Agnello, PhD; Leslie Priddy, BS; Danlee Enzler, BS; Jason F. Wiggins, BS; Christopher Daige; Jessica Van Cleef; | Combination Immunotherapies | Antigen presenting cells; Checkpoint blockade; Costimulation; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P505 | Abscopal immunity achieved via in situ vaccination using a novel combination of cryoablation and Interleukin-12 | Maura R. Vrabel; Francis B. Gillam, PhD; Jared J. Hopkins; Khue G. Nguyen, PhD; David A. Zaharoff, PhD; David A. Zaharoff, PhD; | Combination Immunotherapies | Immune adjuvant; Inflammation; Neoantigens; Solid tumors; Tumor antigens; Tumor microenvironment; Vaccine |
| P506 | Targeting inflammation in the tumor micro-environment to improve radiation and immunotherapy | Debashree Basudhar, PhD; Veena Somasundaram, PhD; Robert Cheng; David A. Scheiblin; Erika Palmieri; William F. Heinz; Noemi Kedei; Jinqiu Chen; Daniel W. McVicar, PhD; Stephen J. Lockett; David A. Wink; Lisa Ridnour, PhD; Debashree Basudhar, PhD; | Combination Immunotherapies | Biomarkers; Checkpoint blockade; Immune suppression; Inflammation; Monocyte/Macrophage; Radiotherapy; T cell; Targeted therapy; Tumor microenvironment |
| P508 | Combination of a radiation-enhancing nanoparticle, radiotherapy,and immune checkpoint inhibitors for treating metastasized lung cancer in mice | Yun Hu; James Welsh; Sébastien PARIS; Angelica M. Cortez; | Combination Immunotherapies | Checkpoint blockade; Radiotherapy; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs) |
| P509 | Myeloid Cell-Selective STAT3 Inhibition Sensitizes Head and Neck Cancers to Radiation Therapy and Stimulates T-cell-Dependent Tumor Regression | Marcin Kortylewski, PhD; Dayson F. Moreira, PhD; Marcin Kortylewski, PhD; Sagus Sampath; Haejung Won; Chongkai Wang; Peter P. Lee, MD; Ellie Maghami; Erminia Massarelli, MD, PhD, MS; William C. Spanos, MD; Seok White; | Combination Immunotherapies | Clinical study; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; Radiotherapy; Solid tumors; TLR; Tumor microenvironment |
| P510 | Treatment of murine mammary carcinoma with focal radiation and immune checkpoint inhibition results in reduced immune suppression and enhanced cytotoxic immune cell activity | Philip E. Lapinski, PhD; Maryland Franklin, PhD; David Draper, PhD; Scott Wise, BS; | Combination Immunotherapies | B cell; Checkpoint blockade; Immune suppression; NK/NK T cell; Radiotherapy; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P511 | Mechanistic insights into combination low dose targeted radionuclide and checkpoint blockade treatment to turn a “cold” tumor “hot” | Ravi Patel, MD, PhD; Reinier Hernandez, PhD; Peter M. Carlson, BS; Ryan Brown; Luke Zangl; Amber Bates; Ian Arthur; Justin C. Jagodinsky; Joseph Grudinski; Amy K. Erbe, PhD; Jamey Weichert; Paul M. Sondel, MD, PhD; Zachary S. Morris, MD, PhD; Ravi Patel, MD, PhD; | Combination Immunotherapies | Checkpoint blockade; Radiotherapy; Solid tumors; Targeted therapy; Tumor microenvironment |
| P512 | Efficacy of combined radio- and immuno-therapies vs. radiotherapy alone in the treatment of brain metastases: a systematic review and meta-analysis | Kirill Peskov; Veronika Voronova; Svetlana Lebedeva; Marina Sekacheva; Gabriel Helmlinger, PhD; | Combination Immunotherapies | Immune tolerance; Radiotherapy; Solid tumors |
| P513 | Radiation therapy as a tool to optimize immunomodulation by cell cycle inhibitors in HR+ breast cancer | Giulia Petroni; Aitziber Buqué Martinez; Maurizio Di Liberto; Takahiro Yamazaki, PhD; Norma Bloy; Ai Sato; Selina Chen-Kiang; Silvia Formenti, MD; Lorenzo Galluzzi; | Combination Immunotherapies | Cytokine; Radiotherapy; Solid tumors; Targeted therapy |
| P514 | Molecularly targeted radionuclide therapy modulates the composition of the murine prostate cancer microenvironment | Hemanth K. Potluri, BA; Reinier Hernandez, PhD; Christopher W. Zahm, PhD; Joseph Grudzinski, PhD; Christopher Massey; Jamey Weichert, PhD; Douglas G. McNeel, MD, PhD; | Combination Immunotherapies | MDSC; Radiotherapy; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| P515 | Defining the TCR repertoire and functional differentiation of tumor-infiltrating T cells in mice responding to radiotherapy and CTLA-4 blockade | Nils-Petter Rudqvist, PhD; Claire Lhullier, PhD; Erik Wennerberg, PhD; Jennifer Sims, PhD; Sandra Demaria, MD; | Combination Immunotherapies | Checkpoint blockade; Immune monitoring; Radiotherapy; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P516 | Radiation-driven changes in immunomodulatory DNA cargo of exosomes produced by cancer cells | Sheila Spada, PhD; Sandra Demaria, MD; Sheila Spada, PhD; Nils-Petter Rudqvist, PhD; Tuo Zhang, PhD; | Combination Immunotherapies | Dendritic cell; Immune contexture; Radiotherapy; Solid tumors |
| P517 | Potent anti-tumor effect of systemically administered nanoparticles containing a TLR7 agonist in combination with radiotherapy | Camilla Stavnsbjerg, MSc; Esben Christensen, MSc; Rasmus Münter, MSc; Andreas Kjær, MD, PhD; Svetlana Panina, MD, PhD; Martin Bak, PhD; Jonas R. Henriksen, PhD; Simon Jensen, PhD; Anders E. Hansen, DVM, PhD; Thomas L. Andresen, PhD; | Combination Immunotherapies | Antigen presenting cells; Immune adjuvant; Myeloid cells; Radiotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor antigens; Tumor microenvironment |
| P518 | Testing a new platform for precision use of radiation therapy to induce in situ vaccination in breast cancer | Samantha J. Van Nest, PhD; Tasnim Anika; Adriana Irizarry; Laura Martin; Giorgio Inghirami; Silvia Formenti, MD; Sandra Demaria, MD; Samantha J. Van Nest, PhD; | Combination Immunotherapies | Biomarkers; Checkpoint blockade; Radiotherapy; Vaccine |
| P519 | Immunogel - an intratumoral multi-drug sustained release technology that polarizes the tumor microenvironment towards a proinflammatory and immunosupportive state | Trine B. Engel, PhD; Jennifer S. Jørgensen, PhD; Lars Ringgaard, PhD; Fredrik Melander, PhD; Sophie B. Jensen, MSc; Linda M. Bruun, PhD; Camilla Stavnsbjerg, MSc; Andreas Tue I. Jensen, PhD; Julianna Thuróczy, DVM, PhD, Dipl. ECAR; Lajos Balogh, DVM, PhD; Frederikke P. Fliedner, MSc; Martin Bak, PhD; Andreas Kjær, MD, PhD; Jonas R. Henriksen, PhD; Anders E. Hansen, DVM, PhD; Thomas L. Andresen, PhD; | Combination Immunotherapies | Checkpoint blockade; Chemotherapy; Radiotherapy; Solid tumors; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
| P520 | Matching-adjusted indirect comparison of pembrolizumab plus axitinib versus nivolumab plus ipilimumab for the first-line treatment of advanced/ metastatic renal cell carcinoma | Yufei Wang; Yichen Zhong, PhD; Shahrul Mt-Isa; Rodolfo Perini, MD; Oluwakayode Adejoro, MD, MPH; Oluwakayode Adejoro, MD, MPH; Oluwakayode Adejoro, MD, MPH; | Combination Immunotherapies | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; Targeted therapy |
| P521 | MEK inhibition enhances oncolytic herpes virus immunotherapy | Praveen K. Bommareddy, MS, PhD; Andrew Zloza, MD, PhD; Samuel Rabkin, PhD; Howard L. Kaufman, MD, FACS; | Combination Immunotherapies | Checkpoint blockade; Dendritic cell; Gene expression; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment |
| P522 | Preclinical development of M4112, an IDO1/TDO2 dual selective and orally bioavailable small molecule inhibitor, and combination with avelumab, for treatment of solid tumors | Jieqing Chen, MD; Chia Lin Chu, PhD; Feng Jiang, PhD; Chunxiao Xu, PhD; Yanping Zhang; Sireesha Yalavarthi; Molly Coop; Hong Wang; Yanyan Wang; Bettina Hanschke; Anindya Siddharta; Sen Zhang; Amit Deshpande; Bartholomew Naughton, PhD; Filippos Porichis; Tai-An Lin, PhD; Joern-Peter Halle; Tilo Senger; Brian Sherer; Jacques Moisan; | Combination Immunotherapies | Checkpoint blockade; Coinhibition; Immune suppression; Metabolism; Solid tumors; Tumor evasion; Tumor microenvironment |
| P523 | Immunotherapy plus gene therapy: A tumor-targeting nanomedicine carrying the TP53 gene crosses the blood–brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma | Joe B. Harford, PhD; Sang-Soo Kim, PhD; Manish Moghe; Caroline Doherty; Esther H. Chang, PhD; | Combination Immunotherapies | Biomarkers; Checkpoint blockade; Dendritic cell; Gene expression; Immune suppression; NK/NK T cell; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P524 | CRISPR CAS9 mediated BRCA1 knockout modulates the tumor infiltrating lymphocytes landscape and cytokine profile in a murine breast cancer model | Julia Schuler; Anya Avrutskaya; Kanstantsin Lashuk; Mariette Heins, PharmD; Cordula Tschuch; Astrid Jensen; Gerhard Kelter; Anne-Lise Peille; Maycee Robinson; William Durham; Armin Mayer; Anne-Marie Zuurmond; | Combination Immunotherapies | Checkpoint blockade; Monocyte/Macrophage; MDSC; NK/NK T cell; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P525 | Dose-dependent sensitization of combined anti-angiogenic and PD-1 blockade in breast cancer | Wen Jiang, MD, PhD; Yifan Wang, PhD; Betty Y. Kim; Jieqiong Liu, MD, PhD; | Combination Immunotherapies | Angiogenesis; T cell; Targeted therapy; Tumor microenvironment |
| P526 | Combination cabozantinib and nivolumab treatment in patients with refractory metastatic renal cell carcinoma (mRCC) | Emily N. Kinsey, MD; Landon C. Brown, MD; Chester Kao, MD; Patrick Healy; Michael R. Harrison, MD; Megan A. McNamara, MD; Andrew J. Armstrong, MD; Sundhar Ramalingham, MD; Daniel J. George, MD; Tian Zhang, MD; | Combination Immunotherapies | Checkpoint blockade; Immune toxicity; Solid tumors; Targeted therapy |
| P527 | IgE-based therapeutic strategy against pancreatic cancer | Kamiya Mehla, PhD; Ragupathy Madiyalakan, PhD; Christopher Nicodemus, MD; Thomas Caffrey; Michael A. Hollingsworth, PhD; kelly A. O' connell; | Combination Immunotherapies | Antibody; Dendritic cell; Immune adjuvant; NK/NK T cell; Solid tumors; T cell; Targeted therapy; TLR; Tumor antigens; Tumor microenvironment |
| P528 | Combination antibody treatment targeting PD-L1 and 4-1BB leads to reduced anti-tumor immunity against CT26 tumors in B-cell deficient JH-/- mice | Zhengming Yan; Heather Llewellyn; Kerry Kelleher; Bernadette Pascual; Angela Stauffer; Ying Ding; Xiaorong Li; Mark Ozeck; Jeffrey Toste; Han Yang; Haikuo Zhang; Sripad Ram, PhD; Sripad Ram, PhD; Sripad Ram, PhD; Cathy Zhang; | Combination Immunotherapies | Antibody; B cell; Checkpoint blockade; Immune contexture; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P529 | A tumor microenvironment-recognizable polymeric conjugate for antigen delivery and cancer immunotherapy | Jung Min Shin; Seok Ho Song; Jae Ah Lee; Jae Hyung Park, PhD; | Combination Immunotherapies | T cell; Targeted therapy; Tumor microenvironment; Vaccine |
| P530 | Blockade of IDO/TDO downstream effectors restricts a Treg-macrophage suppressive axis and resistance to anti-PD-1 therapy | Luis F. Campesato, PhD; Sadna Budhu, PhD; Jeremy H. Tchaicha, PhD; Mathieu Gigoux, PhD; Ivan Cohen; Levi M. Mangarin, BS; David Redmond; Stephane Pourpe; Cailian Liu, MD; Roberta Zappasodi, PhD; Dmitriy Zamarin, MD, PhD; Mark Manfredi, PhD; Karen McGovern, PhD; Taha Merghoub, PhD; Jedd D. Wolchok, MD, PhD; Luis F. Campesato, PhD; | Combination Immunotherapies | Checkpoint blockade; Immune suppression; Immune tolerance; Monocyte/Macrophage; Myeloid cells; Metabolism; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P531 | A Tumor PD-L1-NLRP3 Inflammasome Signaling Axis Drives Adaptive Resistance to Anti-PD-1 Immunotherapy | Balamayooran Theivanthiran, PhD; Kathy Evans, BS; Nicholas DeVito, MD; Michael Plebanek, PhD; Michael Sturdivant, BS.; Alisha H. Holtzhausen, PhD; Luke P. Wachsmuth, BS.; April Salama, MD; Yubin Kang, MD; David Hsu, MD, PhD; Justin M. Balko, PhD, PharmD; Douglas B. Johnson, MD, MSCI; Mark Starr, BS.; Andrew Nixon, PhD; Brent A. Hanks, MD, PhD; | Combination Immunotherapies | Checkpoint blockade; Chemokine; Gene expression; Immune suppression; MDSC; Proteomics; Solid tumors; TLR; Tumor evasion; Tumor microenvironment |
| P532 | Increased adiposity reduces the response rate to a combinatorial CTLA-4 based therapy in diet-matched, renal tumor-bearing mice without substantially altering intra-tumoral T cell profiles | William J. Turbitt, Jr., PhD; Shannon Boi; Rachael M. Orlandella, BS; Justin T. Gibson, BS; Lyse A. Norian, PhD; | Combination Immunotherapies | Checkpoint blockade; Gene expression; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P715 | Strategies to mitigate immune-related adverse events of efficacious combination immunotherapies in preclinical models of cancer | Célia Jacoberger-Foissac, PhD; Stephen J. Blake; Célia Jacoberger-Foissac, PhD; Jing Liu; Stacey Allen; Juming Yan; Heidi Harjunpaa; Mark J. Smyth; Michele W. Teng, PhD; | Immunotherapy Toxicities | Antibody; Autoimmunity; Cytokine; Immune suppression; Immune toxicity; Regulatory T cell (Treg cell); Solid tumors |
| P855 | High-resolution maps of heterogeneous antigen expression in glioblastoma and implications for immunotherapy | Michael Barish, PhD, Lihong Weng, Dina Awabdeh, MD, Blake Brewster, Massimo D'Apuzzo, Yubo Zhai, Alfonso Brito, Brenda Chang, Annie Sarkissian, Renate Starr, MS, Wen-Chung Chang, Brenda Aguilar, BS, Araceli Naranjo, Suzette Blanchard, Russell Rockne, PhD, Behnam Badie, MD, Vanessa Jonsson, PhD, Stephen Forman, MD, Christine Brown, PhD , Michael Barish, PhD | Combination Immunotherapies | Adoptive immunotherapy; CAR T cells; Solid tumors; Targeted therapy; Tumor antigens |
© 2019 Society for Immunotherapy of Cancer (SITC). All rights reserved. SITC Meeting Code of Conduct.
